Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "credit fc26 Visitez le site Buyfc26coins.com La référence incontestée pour les FC 26 coins.VIiF"

Looking for quality documents?
publications icon
Ultrafiltration Behavior of Partially Retained Proteins and Completely Retained Proteins Using Equally-Staged Single Pass Tangential Flow Filtration Membranes
publications icon
Biogen Inc.: Comparison of Protein Concentration Determination of a mAb Drug Substance Using Variable Pathlength Spectroscopy and UV-VIS Spectroscopy Publication
external link icon
Repligen Announces Licensing Agreement with Pfizer for Spinal Muscular Atrophy Program
Repligen Corporation (NASDAQ:RGEN) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Repligen’s spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA). The SMA program includes RG3039, a small molecule drug candidate in clinical development for SMA, as well as backup compounds and enabling technologies. Under the terms of the agreement, Repligen is entitled to receive up to $70 million from Pfizer, commencing with an upfront payment of $5 million and total potential future milestone payments of up to $65 million as well as royalties on any future sales of SMA compounds developed under the agreement. SMA is an orphan neurodegenerative genetic disease that presents early in life. “This agreement is consistent with the strategic decision we announced in August 2012 to focus Repligen’s internal efforts on the growth of our bioprocessing business, while seeking external partners for our
external link icon
Repligen Reports Positive Results from Phase 1 Clinical Trial of RG3039 for Spinal Muscular Atrophy
external link icon
Repligen Announces Acquisition of Chromatography Technology Platform "Plug and Play" Products Create Broad Opportunity in Biopharmaceutical Manufacturing
external link icon
Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand
WALTHAM, Mass., June 28, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into an agreement with Purolite Life Sciences to supply its next-generation Protein A ligand, NGL-Impact™ A,  which will be commercialized by Purolite Life Sciences using their novel Praesto® agarose jetting base bead technology. Repligen is a longtime market leader in Protein A, with two facilities that produce the majority of the global Protein A ligand demand to biopharmaceutical customers worldwide. NGL-Impact™ A was developed as part of Repligen’s collaboration with Navigo Proteins GmbH. This new ligand has outstanding performance attributes when immobilized on jetted agarose bead technology, with ultra-high binding capacities and excellent alkaline stability. These attributes are important in providing improved monoclonal antibody capture to handle increased upstream product titres, and in
external link icon
Repligen Announces Proposed Public Offering of $100 Million of Convertible Senior Notes due 2021
WALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) (the “Company”) has commenced an offering of $100 million aggregate principal amount of Convertible Senior Notes due 2021 (the “Notes”) in an underwritten offering which includes the grant to the underwriter of a 30-day option to purchase up to an additional $15 million aggregate principal amount of Notes.  Jefferies is the sole book-running manager for the offering. 
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  The Notes will be issued and sold pursuant to an automatically effective shelf registration statement (including a base prospectus) that was previously filed with the Securities and Exchange Commission (“SEC”). A preliminary prospectus supplement relating to this offering will be filed with the SEC. When available, copies of the
publications icon
Gold Particle/Virus Filtration Testing Using Slope Spectroscopy Publication
publications icon
Takeda: Validating the Gold Nanoparticle Test with the CTech™ SoloVPE® System Publication
publications icon
KB19003 FlowVPE Software-Security Configuration Windows 710-32-64 CaryWinUV Article
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support